Is Wegovy available on the NHS in Scotland?

Does NHS Scotland fund Wegovy, and through which services?

Yes, NHS Scotland does fund semaglutide (Wegovy) for weight management, but the route is specific. Access is through specialist weight management services (multidisciplinary teams that typically include a dietitian, a psychologist and a doctor) rather than a standard GP appointment. The Scottish Medicines Consortium (SMC) accepted semaglutide for use within NHS Scotland for weight management, but its acceptance sits within the broader framework of Tier 3 and Tier 4 weight management pathways. In practice, that means your GP refers you to a specialist service, and the specialist service then decides whether injectable treatment is appropriate as part of a wider programme.

This is a meaningful distinction. Getting a GP referral does not guarantee treatment; it gets you into a queue for an assessment. Some health boards have invested significantly in these pathways; others are still building capacity. The result is that availability genuinely varies depending on which Scottish health board you live under, NHS Greater Glasgow and Clyde operates differently from, say, NHS Highland or NHS Lothian. If you are curious about provision in your area, your GP practice is the right starting point, though our detailed guide to Wegovy on the NHS in Scotland covers what different boards have published about their pathways.

What are the eligibility criteria for Wegovy in Scotland on the NHS?

A question our prescribers hear most weeks is whether the NICE TA875 criteria (the guidance that recommends Wegovy for adults with a BMI of 35 or above and at least one weight-related condition, within a specialist service for up to two years) apply automatically in Scotland. They do not. NICE guidance covers England and Wales; NHS Scotland operates under SMC guidance and its own clinical policies. In practice the clinical thresholds are broadly similar (a BMI of 35 or above, with a comorbidity such as type 2 diabetes, hypertension or obstructive sleep apnoea), but the commissioning decisions, funding priorities and service configurations are set by individual health boards.

Lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds (typically around 2.5 kg/m² lower) reflecting the higher cardiometabolic risk at lower BMIs in these groups. A broader overview of how semaglutide sits within NHS access arrangements is available on our semaglutide NHS access page. One point worth knowing: NHS Scotland's criteria mean you may meet the clinical case for treatment without meeting the specific thresholds a particular health board has set for funded access. The two things are not the same.

How does Scotland's NHS approach compare with England's recent rollout?

England has been rolling out tirzepatide (Mounjaro) through GP practices under the 2026/27 GP contract, with a phased eligibility schedule based on BMI and the number of qualifying conditions a patient has. That programme is specific to NHS England; it does not extend to Scotland. Scotland is not following the same phased tirzepatide rollout, at least not on the same timetable or through the same primary-care route. If you have read about NHS England's expanding access to weight-loss injections and wondered whether it applies to you as a Scottish patient, the honest answer is: not directly.

For a more detailed comparison of timelines and what the England rollout actually means for patients on either side of the border, our page on when Wegovy is available on the NHS sets out what has changed and when. Separately, our broader NHS Wegovy access guide covers the England and Wales picture if you need to compare the two systems side by side.

What are the realistic private alternatives if NHS access is out of reach?

For adults who meet the clinical criteria for Wegovy (a BMI of 30 or above, or 27 or above with a weight-related condition) but who cannot get an NHS referral, face a long wait, or simply prefer a more immediate and flexible route, a private prescription through a GPhC-registered pharmacy is a fully legal option. The clinical criteria for private treatment are set by the licensed indication and the prescriber's clinical judgment; you still need a genuine consultation, identity verification and a review by a qualified prescriber. You can read about how semaglutide prescription works privately on our Wegovy access page.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber (a real clinician, not an automated system) on the same day you submit it. If treatment is clinically appropriate, your prescription is dispatched the same day (orders placed before 12pm, Monday to Friday) and arrives free via tracked DPD delivery the next working day, in plain packaging. There are no subscriptions and no hidden charges: one transparent price covers the consultation, prescription, treatment and aftercare. If you want to understand more about the Wegovy injection itself before starting, our Wegovy overview page covers how semaglutide works, the dosing schedule and what to expect. To explore whether treatment is right for you, check your eligibility with our prescribers.